N- (4- doxorubicin- N- carbonyl(oxymethyl)phenyl)- O- glucuronyl carbamate

Also Known As:

DOX-GA3

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthacenes
        Anthracyclines: 9423
        Daunorubicin: 2641
        Doxorubicin: 35390
        N-(4-doxorubicin-N-carbonyl(oxymethyl)phenyl)-O-glucuronyl carbamate: 5
- Carboxylic Acids: 973
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthacenes
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        N-(4-doxorubicin-N-carbonyl(oxymethyl)phenyl)-O-glucuronyl carbamate: 5
Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        N-(4-doxorubicin-N-carbonyl(oxymethyl)phenyl)-O-glucuronyl carbamate: 5
- Sugar Acids: 4
  - Uronic Acids: 152
    - Glucuronates: 3
      - N-(4-doxorubicin-N-carbonyl(oxymethyl)phenyl)-O-glucuronyl carbamate: 5

Experts

1.	Boven, Epie: 2 articles (12/2004 - 03/2004)
2.	Haisma, Hidde J: 2 articles (12/2004 - 03/2004)
3.	Pinedo, Herbert M: 2 articles (12/2004 - 03/2004)
4.	de Graaf, Michelle: 2 articles (12/2004 - 03/2004)
5.	Boven, E: 2 articles (02/2001 - 02/2001)
6.	Haisma, H J: 2 articles (02/2001 - 02/2001)
7.	Houba, P H: 2 articles (02/2001 - 02/2001)
8.	Leenders, R G: 2 articles (02/2001 - 02/2001)
9.	Pinedo, H M: 2 articles (02/2001 - 02/2001)
10.	Scheeren, J W: 2 articles (02/2001 - 02/2001)

Related Diseases

1.	Neoplasms (Cancer) 02/15/2001 - "As a result of ADEPT, the number of regressions of tumors improved from 0 out of 12 to 9 out of 11 at a dose of 250 mg/kg DOX-GA3. " 03/01/2004 - "Intratumoral administration of Ad/C28-GUSh before DOX-GA3 enhanced the growth inhibition and increased the tumor volume-doubling time to 43.1 days (p < 0.01), while virus alone had no effect. " 02/15/2001 - "At the lower dose of 250 mg/kg DOX-GA3 tumor growth inhibition (34%) was not better than that of DOX. " 02/15/2001 - "Treatment with DOX-GA3 at a single dose of 500 mg/kg resulted in a better tumor growth inhibition of 87%. " 12/01/2004 - "Intravenous administration of DOX-mGA3 in FMa-bearing mice resulted in an area under the concentration versus time curve (AUC) of DOX-GA3 in tumor and most normal tissues that was 2.5- to 3-fold higher than after the same dose of DOX-GA3 itself. "
2.	Ovarian Neoplasms (Ovarian Cancer) 02/15/2001 - "human ovarian cancer xenografts (FMa) the maximum tolerated dose (MTD) of DOX-GA3 (500 mg/kg weekly x 2) was much higher when compared with that of DOX (8 mg/kg weekly x 2). " 02/01/2001 - "The pharmacokinetics and distribution of DOX-GA3 in nude mice bearing human ovarian cancer xenografts (OVCAR-3) were determined and compared with DOX. " 02/15/2001 - "In vitro, the prodrug DOX-GA3 was found to be 12-times less toxic than the parent drug DOX in a human ovarian cancer cell line. " 03/01/2004 - "Treatment of well-established FMa human ovarian cancer xenografts with intravenous injection of DOX-GA3 (500 mg/kg) resulted in a tumor volume-doubling time of 23.8 days compared to 8.0 days for phosphate-buffered saline (PBS)-treated mice. " 02/01/2001 - "A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer."
3.	Prostatic Neoplasms (Prostate Cancer) 03/01/2016 - "Selective and augmented β-glucuronidase expression combined with DOX-GA3 application elicits the potent suppression of prostate cancer."
4.	Necrosis 02/01/2001 - "Treatment with DOX-GA3 was also given to mice with larger tumours containing more necrosis. "

Related Drugs and Biologics

1.	Prodrugs
2.	Immunoconjugates (Immunoconjugate)
3.	Enzymes
4.	Glucuronides
5.	Glucuronidase
6.	Doxorubicin (Adriamycin)
7.	Phosphates (Orthophosphate)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intravenous Administration
3.	Intravenous Injections